https://www.pharmaradar360.com/article/why-you-really-shouldn-t-overcook-your-proteins-e42fa4a2df65e838PharmaRadar360en2026-09-17T12:00:00.000ZWhy you really shouldn't overcook your proteinshttps://www.pharmaradar360.com/article/futbol-femenino-profesional-un-trabajo-ademas-de-un-juego-4f14ae7a4b93a32dPharmaRadar360en2026-09-17T11:40:49.000ZFútbol femenino profesional. Un trabajo, además de un juegohttps://www.pharmaradar360.com/article/tiziana-life-sciences-announces-signing-of-mou-with-king-abdullah-international-391b307649c2487bPharmaRadar360en2026-09-17T11:00:00.000ZTiziana Life Sciences Announces Signing of MOU with King Abdullah International Medical Research Centerhttps://www.pharmaradar360.com/article/cyllene-therapeutics-appoints-seasoned-biotech-executive-dr-marc-grasso-as-chief-b2a33d9a332c8832PharmaRadar360en2026-09-17T11:00:00.000ZCyllene Therapeutics Appoints Seasoned Biotech Executive Dr Marc Grasso as Chief Financial Officerhttps://www.pharmaradar360.com/article/hovione-pharmaceutical-company-opens-31k-sq-ft-facility-in-east-windsor-adding-a-63b3a40a0c111755PharmaRadar360en2026-09-17T11:00:00.000ZHovione Pharmaceutical Company Opens 31K Sq. Ft. Facility in East Windsor, Adding Area Jobshttps://www.pharmaradar360.com/article/bristol-myers-squibb-presents-sotyktu-deucravacitinib-data-showing-durable-effic-ab59c6531d46fb79PharmaRadar360en2026-09-17T10:59:00.000ZBristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Yearshttps://www.pharmaradar360.com/article/novo-explores-macrocycles-potential-in-1-4b-cardiometabolic-pact-with-danish-bio-83b246e22760048dPharmaRadar360en2026-09-17T10:56:49.000ZNovo explores macrocycles’ potential in $1.4B cardiometabolic pact with Danish biotechhttps://www.pharmaradar360.com/article/70mg-4ml-962d855db4c60637PharmaRadar360en2026-09-17T10:35:10.000Z「ミリプラ動注用70mg」ならびに「ミリプラ用懸濁用液4mL」販売中止予定のご案内（住友ファーマ株式会社）https://www.pharmaradar360.com/article/a-sellas-immunotherapy-study-long-delayed-will-end-in-failure-4f39356374c8bccbPharmaRadar360en2026-09-17T10:34:38.000ZA Sellas immunotherapy study, long delayed, will end in failurehttps://www.pharmaradar360.com/article/a-biotech-hedge-fund-births-a-new-immunology-company-81b7beb45c9e906fPharmaRadar360en2026-09-17T10:34:38.000ZA biotech hedge fund births a new immunology companyhttps://www.pharmaradar360.com/article/innate-pharma-ipha-extends-cash-runway-to-q1-2028-after-sobi-deal-and-30m-share-356bebb27c4a8704PharmaRadar360en2026-09-17T10:34:07.000ZInnate Pharma (IPHA) extends cash runway to Q1 2028 after Sobi deal and €30M share salehttps://www.pharmaradar360.com/article/fda-ordered-studies-of-many-drugs-devices-on-the-market-are-not-done-86a4a800b65f63b0PharmaRadar360en2026-09-17T10:32:46.000ZFDA-ordered studies of many drugs, devices on the market are not donehttps://www.pharmaradar360.com/article/children-s-public-health-nursing-workforce-and-activity-2025-cf1dc915acbdddd5PharmaRadar360en2026-09-17T10:26:17.000ZChildren’s public health nursing: workforce and activity, 2025https://www.pharmaradar360.com/article/upfront-cash-hits-innate-pharma-ipha-as-lymphoma-drug-pact-takes-effect-b9face9e737abc29PharmaRadar360en2026-09-17T10:22:02.000ZUpfront cash hits Innate Pharma (IPHA) as lymphoma drug pact takes effecthttps://www.pharmaradar360.com/article/pharmaceutical-companies-prepare-production-in-orbit-channel-newsasia-69453acee50ff8baPharmaRadar360en2026-09-17T10:18:24.000ZPharmaceutical companies prepare production in orbit — Channel NewsAsiahttps://www.pharmaradar360.com/article/southnord-artfest-2026-roots-en-route-bee1bb7e9ad69218PharmaRadar360en2026-09-17T10:10:08.000ZSouthnord Artfest 2026: Roots En Routehttps://www.pharmaradar360.com/article/get-the-care-you-need-where-you-need-it-df971658819361e2PharmaRadar360en2026-09-17T10:08:14.000ZGet the care you need, where you need ithttps://www.pharmaradar360.com/article/17-09-il-policlinico-di-milano-si-illumina-di-arancione-per-la-giornata-nazional-0f6043cd33accc74PharmaRadar360en2026-09-17T10:00:00.000Z[17.09] Il Policlinico di Milano si illumina di arancione per la Giornata Nazionale della Sicurezza delle Curehttps://www.pharmaradar360.com/article/universite-paris-cite-stands-out-once-again-in-the-2026-shanghai-thematic-rankin-46ce1d0268d638fcPharmaRadar360en2026-09-17T09:43:48.000ZUniversité Paris Cité stands out once again in the 2026 Shanghai thematic rankinghttps://www.pharmaradar360.com/article/swiss-company-roche-succeeds-in-phase-3-trial-of-cancer-drug-6ebb3f484a643754PharmaRadar360en2026-09-17T09:42:00.000ZSwiss company Roche succeeds in phase 3 trial of cancer drughttps://www.pharmaradar360.com/article/pharma-be-on-tour-2026-klinische-studies-zijn-een-strategisch-pluspunt-voor-pati-78f02618f856aad7PharmaRadar360en2026-09-17T09:22:08.000Zpharma.be On Tour 2026: Klinische studies zijn een strategisch pluspunt voor patiënten en de toekomst van Belgiëhttps://www.pharmaradar360.com/article/china-has-a-grip-on-america-s-pharmaceutical-industry-and-that-s-a-threat-on-nat-56163250b91fc512PharmaRadar360en2026-09-17T09:13:21.000ZChina Has a Grip on America's Pharmaceutical Industry and That's a Threat on National Securityhttps://www.pharmaradar360.com/article/belgie-moet-zijn-ambitie-om-de-biofarmaceutische-sector-te-ondersteunen-hard-mak-2e04da875ecb2b0ePharmaRadar360en2026-09-17T09:05:53.000ZBelgië moet zijn ambitie om de biofarmaceutische sector te ondersteunen hard makenhttps://www.pharmaradar360.com/article/life-changing-cancer-treatment-could-transform-care-for-autoimmune-conditions-664000b9a06fd29fPharmaRadar360en2026-09-17T09:03:20.000ZLife-changing cancer treatment could transform care for autoimmune conditionshttps://www.pharmaradar360.com/article/boehringer-halts-phase-iii-kidney-trial-of-vicadrostat-jardiance-combination-0741a91de32987dePharmaRadar360en2026-09-17T08:57:11.000ZBoehringer halts Phase III kidney trial of vicadrostat/Jardiance combinationhttps://www.pharmaradar360.com/article/benchmarking-the-foundation-of-reliable-ai-in-biomedicine-b0c86ba0d683f2e0PharmaRadar360en2026-09-17T08:56:04.000ZBenchmarking: the foundation of reliable AI in biomedicinehttps://www.pharmaradar360.com/article/longeveron-s-phase-2b-stem-cell-flop-spurs-cost-cutting-exploration-of-all-optio-5a694be2f452f7d3PharmaRadar360en2026-09-17T08:44:59.000ZLongeveron’s phase 2b stem cell flop spurs cost cutting, exploration of ‘all options’https://www.pharmaradar360.com/article/tukaram-mundhe-s-fda-overhaul-how-a-food-safety-watchdog-is-now-taking-on-drug-p-01800e1d63a9af9fPharmaRadar360en2026-09-17T08:33:15.000ZTukaram Mundhe’s FDA overhaul: How a food safety watchdog is now taking on drug prices and healthcare...https://www.pharmaradar360.com/article/measles-epidemiology-2023-to-2026-1387e9c40489bd37PharmaRadar360en2026-09-17T08:30:09.000ZMeasles epidemiology 2023 to 2026https://www.pharmaradar360.com/article/environmental-monitoring-following-the-grenfell-tower-fire-85d5cc3f2b36adbcPharmaRadar360en2026-09-17T08:30:09.000ZEnvironmental monitoring following the Grenfell Tower firehttps://www.pharmaradar360.com/article/salmonella-outbreak-update-dbba55fa25793323PharmaRadar360en2026-09-17T08:30:09.000ZSalmonella outbreak updatehttps://www.pharmaradar360.com/article/bioscience-and-health-technology-sector-statistics-2024-to-2025-76d66d939a9818b2PharmaRadar360en2026-09-17T08:30:07.000ZBioscience and health technology sector statistics 2024 to 2025https://www.pharmaradar360.com/article/salmonella-statistical-releases-5659a2d745797007PharmaRadar360en2026-09-17T08:30:07.000ZSalmonella statistical releaseshttps://www.pharmaradar360.com/article/bioscience-and-health-technology-sector-statistics-6c8da0610eecb0b8PharmaRadar360en2026-09-17T08:30:07.000ZBioscience and health technology sector statisticshttps://www.pharmaradar360.com/article/informationstag-pankreaszysten-wann-ist-eine-behandlung-notwendig-e06e284e6f7f97efPharmaRadar360en2026-09-17T08:30:00.000ZInformationstag Pankreaszysten: Wann ist eine Behandlung notwendig?https://www.pharmaradar360.com/article/2-2026-217279a39fb91d0dPharmaRadar360en2026-09-17T08:27:53.000ZΟΡΘΗ ΕΠΑΝΑΛΗΨΗ_Τελικές Προτεινόμενες _ Νέα 2ου Τριμήνου 2026 _ Ανατιμολόγηση προϊόντων αναφοράς λόγω λήξης της προστασίας δεδομένων τους _ Μη Αποζημιούμενα: αναπροσαρμογή τιμήςhttps://www.pharmaradar360.com/article/first-ancient-dna-sample-in-charm-taken-7ea859beb4536cb7PharmaRadar360en2026-09-17T08:25:45.000ZFirst ancient DNA sample in CHARM taken!https://www.pharmaradar360.com/article/migrant-health-guide-bdf31ac2db51f874PharmaRadar360en2026-09-17T08:16:27.000ZMigrant health guidehttps://www.pharmaradar360.com/article/camera-lights-action-3fcd3687e1668da6PharmaRadar360en2026-09-17T08:15:03.000ZCamera, lights - action!https://www.pharmaradar360.com/article/immunisation-patient-group-direction-pgd-templates-1af7ede7c1c283c6PharmaRadar360en2026-09-17T08:05:49.000ZImmunisation patient group direction (PGD) templateshttps://www.pharmaradar360.com/article/abbvie-connects-with-120-korean-biotechs-in-search-for-r-d-licensing-deals-6032fe94dde44e6fPharmaRadar360en2026-09-17T07:54:17.000ZAbbVie connects with 120 Korean biotechs in search for R&D, licensing dealshttps://www.pharmaradar360.com/article/rtu-packaging-cooperation-is-key-b7cc7f88c1ecb9e2PharmaRadar360en2026-09-17T07:44:19.000ZRTU packaging: cooperation is keyhttps://www.pharmaradar360.com/article/this-tiny-biotech-is-beating-mrna-iova-and-sls-here-s-how-a-billionaire-fueled-i-f9fadbaa2502bed3PharmaRadar360en2026-09-17T07:21:00.000ZThis Tiny Biotech Is Beating MRNA, IOVA And SLS — Here's How A Billionaire Fueled Its September Rallyhttps://www.pharmaradar360.com/article/was-einen-starken-forschungsstandort-ausmacht-c7dadc2f0a981335PharmaRadar360en2026-09-17T07:13:00.000ZWas einen starken Forschungsstandort ausmachthttps://www.pharmaradar360.com/article/idexx-expands-faecal-dx-antigen-testing-platform-in-the-united-kingdom-with-taen-b529781628a7a773PharmaRadar360en2026-09-17T07:00:00.000ZIDEXX Expands Faecal Dx Antigen Testing Platform in the United Kingdom with Taeniid Tapeworm Detectionhttps://www.pharmaradar360.com/article/gemeinsam-die-universitatsmedizin-in-bayern-starken-5e2ecb52b4188f5ePharmaRadar360en2026-09-17T06:59:17.000ZGemeinsam die Universitätsmedizin in Bayern stärkenhttps://www.pharmaradar360.com/article/mmi-marks-five-years-in-state-of-the-art-building-50d06298edd2b99cPharmaRadar360en2026-09-17T06:58:00.000ZMMI marks five years in state-of-the-art buildinghttps://www.pharmaradar360.com/article/title-ix-office-begins-new-professional-development-series-ff66984912be811aPharmaRadar360en2026-09-17T06:56:00.000ZTitle IX office begins new professional development serieshttps://www.pharmaradar360.com/article/three-ai-drug-development-milestones-land-in-a-single-day-as-novo-nordisk-eli-li-84c7a7e7c962ec5ePharmaRadar360en2026-09-17T06:55:00.000ZThree AI drug development milestones land in a single day as Novo Nordisk, Eli Lilly, and ByteDance spin-off ignite China's A-share CRO sectorhttps://www.pharmaradar360.com/article/recognizing-constitution-day-d98419201ae9733fPharmaRadar360en2026-09-17T06:50:00.000ZRecognizing Constitution Dayhttps://www.pharmaradar360.com/article/iii-celestimo-87908e384e7148f6PharmaRadar360en2026-09-17T06:30:00.000Zルンスミオに関するロシュ社の発表について（再発又は難治性濾胞性リンパ腫に対する国際共同第III相CELESTIMO試験のデータ）https://www.pharmaradar360.com/article/roche-announces-phase-iii-celestimo-study-results-for-lunsumio-in-relapsed-or-re-a71e89ddbda78c93PharmaRadar360en2026-09-17T06:30:00.000ZRoche Announces Phase III CELESTIMO Study Results for Lunsumio in Relapsed or Refractory Follicular Lymphomahttps://www.pharmaradar360.com/article/israel-national-biotech-innovation-center-inbi-launches-with-anat-cohen-dayag-as-8dca37929128a225PharmaRadar360en2026-09-17T06:29:07.000ZIsrael National Biotech Innovation Center (INBI) launches with Anat Cohen-Dayag as CEO of INBI Corehttps://www.pharmaradar360.com/article/hong-kong-biotech-stock-roundup-these-are-the-top-performers-in-2026-9150468048a7f3f7PharmaRadar360en2026-09-17T06:24:50.000ZHong Kong biotech stock roundup: These are the top performers in 2026https://www.pharmaradar360.com/article/pune-fda-raids-12-establishments-seizes-food-worth-56-36-lakh-in-festive-food-sa-814c0d81f0358e5ePharmaRadar360en2026-09-17T06:18:01.000ZPune: FDA Raids 12 Establishments, Seizes Food Worth ₹56.36 Lakh In Festive Food Safety Drivehttps://www.pharmaradar360.com/article/teva-price-today-teva-pharmaceutical-industries-limited-stock-price-quote-chart-8ccacc4f83865af8PharmaRadar360en2026-09-17T06:03:42.000ZTEVA Price Today: Teva Pharmaceutical Industries Limited Stock Price, Quote & Chart | MEXChttps://www.pharmaradar360.com/article/charite-startet-zentrale-ki-plattform-fur-klinik-forschung-lehre-und-verwaltung-89e5b497a98fecf5PharmaRadar360en2026-09-17T06:02:18.000ZCharité startet zentrale KI-Plattform für Klinik, Forschung, Lehre und Verwaltunghttps://www.pharmaradar360.com/article/patienternas-erfarenheter-hjalper-varden-att-bli-sakrare-2fd987b01dd45f54PharmaRadar360en2026-09-17T06:00:34.000ZPatienternas erfarenheter hjälper vården att bli säkrarehttps://www.pharmaradar360.com/article/cellules-familiales-c-est-quoi-le-microchimerisme-8a5315b67884f4dcPharmaRadar360en2026-09-17T06:00:00.000ZCellules familiales – C’est quoi le microchimérisme ?https://www.pharmaradar360.com/article/why-is-genscript-biotech-stock-surging-today-cfcf0dd9005195abPharmaRadar360en2026-09-17T05:58:31.000ZWhy is Genscript Biotech stock surging today?https://www.pharmaradar360.com/article/2026-6-10-16-eadf968f3e2a6944PharmaRadar360en2026-09-17T05:22:28.000Z2026年度 第6回 臨床研究講習会開催のお知らせ（10/16開催）https://www.pharmaradar360.com/article/why-is-genscript-biotech-stock-surging-today-by-investing-com-e81c2f3bca3a32c8PharmaRadar360en2026-09-17T05:12:24.000ZWhy is Genscript Biotech stock surging today? By Investing.comhttps://www.pharmaradar360.com/article/new-mesothelioma-drug-turns-cancer-s-own-defenses-against-it-d5f48e25cd3a7e54PharmaRadar360en2026-09-17T05:11:51.000ZNew mesothelioma drug turns cancer’s own defenses against ithttps://www.pharmaradar360.com/article/roche-s-lunsumio-based-regimen-significantly-improves-progression-free-survival-a306a35baacb9b1fPharmaRadar360en2026-09-17T05:00:00.000ZRoche’s Lunsumio-based regimen significantly improves progression-free survival in follicular lymphoma in phase III CELESTIMO studyhttps://www.pharmaradar360.com/article/basic-earnings-per-share-basic-eps-of-gin-hwa-biotech-inc-tpex-7806-f0510930868fe55cPharmaRadar360en2026-09-17T04:30:29.000ZBasic earnings per share (basic EPS) of Gin Hwa Biotech, Inc. – TPEX:7806https://www.pharmaradar360.com/article/tailoring-the-atrioventricular-interval-during-left-bundle-branch-pacing-playing-d55d36d142955481PharmaRadar360en2026-09-17T04:15:19.000ZTailoring the Atrioventricular Interval During Left Bundle Branch Pacing: Playing With Fusionhttps://www.pharmaradar360.com/article/c6051a8af9b974d2PharmaRadar360en2026-09-17T04:14:45.000Zトラスツズマブ デルクステカン適正使用へのご協力のお願い（第一三共株式会社）https://www.pharmaradar360.com/article/05ab89cd21c399c2PharmaRadar360en2026-09-17T04:13:45.000Zダトポタマブ デルクステカン適正使用へのご協力のお願い（第一三共株式会社）https://www.pharmaradar360.com/article/the-morality-of-making-money-by-drug-companies-what-judges-say-61b4f0f088d8ff7fPharmaRadar360en2026-09-17T04:00:00.000ZThe Morality of Making Money by Drug Companies: What Judges Sayhttps://www.pharmaradar360.com/article/scientists-find-a-hidden-health-advantage-in-black-and-green-rice-a1d37df894608434PharmaRadar360en2026-09-17T03:52:12.000ZScientists find a hidden health advantage in black and green ricehttps://www.pharmaradar360.com/article/is-the-pharmaceutical-industry-ushering-in-a-new-narrative-industry-giants-are-c-10a842d86305115cPharmaRadar360en2026-09-17T03:32:43.000ZIs the pharmaceutical industry ushering in a new narrative? Industry giants are collectively pivoting to AI4S, with high‑profile collaborations at home and abroad and the commercialization of cutting‑edge technologies driving momentum. The AI‑driven drug dischttps://www.pharmaradar360.com/article/gilead-accelerates-global-access-planning-for-investigational-once-yearly-lenaca-490cc4e240733c69PharmaRadar360en2026-09-17T03:31:04.000ZGilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Preventionhttps://www.pharmaradar360.com/article/young-discusses-ships-for-america-act-at-hudson-institute-af2fe1a8917adc7fPharmaRadar360en2026-09-17T03:19:43.000ZYoung Discusses SHIPS for America Act at Hudson Institutehttps://www.pharmaradar360.com/article/yakkyokukata-implementation-of-pdg-harmonized-texts-into-japanese-pharmacopoeia-648515e15bc0dc92PharmaRadar360en2026-09-17T03:00:00.000Z[YAKKYOKUKATA]Implementation of PDG harmonized texts into Japanese Pharmacopoeia (Monographs) updatedhttps://www.pharmaradar360.com/article/shinsa-cdx-approved-for-identifying-eligible-patients-updated-622cb0bc906cde46PharmaRadar360en2026-09-17T03:00:00.000Z[SHINSA]CDx approved for identifying eligible patients (Updated)https://www.pharmaradar360.com/article/shinsa-english-translation-of-review-report-opsumit-partial-change-approval-8b926a0ff49051b4PharmaRadar360en2026-09-17T03:00:00.000Z[SHINSA]English Translation of Review Report: Opsumit (Partial Change Approval)https://www.pharmaradar360.com/article/shinsa-list-of-approved-medical-devices-april-2004-to-december-2025-b9c1596fbadb2d5cPharmaRadar360en2026-09-17T03:00:00.000Z[SHINSA]List of Approved Medical Devices: April 2004 to December 2025https://www.pharmaradar360.com/article/hidden-immune-organ-in-the-skull-may-help-fight-brain-cancer-cb58b17dbed624b7PharmaRadar360en2026-09-17T02:43:01.000ZHidden “immune organ” in the skull may help fight brain cancerhttps://www.pharmaradar360.com/article/is-the-pharmaceutical-industry-embracing-a-new-narrative-industry-giants-are-col-2b76358db7efbe16PharmaRadar360en2026-09-17T02:36:44.000ZIs the pharmaceutical industry embracing a new narrative? Industry giants are collectively pivoting toward AI for Science (AI4S), catalyzed by major domestic and international collaborations and technological implementation, marking a critical phase for value rhttps://www.pharmaradar360.com/article/anthropic-s-drug-discovery-partners-ai-pharmaceutical-orders-set-to-double-next-94b555d4be014da6PharmaRadar360en2026-09-17T02:10:56.000ZAnthropic's Drug Discovery Partners: AI Pharmaceutical Orders Set to Double Next Yearhttps://www.pharmaradar360.com/article/passaparola-21-09-120-anni-della-clinica-mangiagalli-celebriamo-la-culla-d-itali-ad444bb0b97c11e5PharmaRadar360en2026-09-17T02:00:00.000Z#PASSAPAROLA [21.09] 120 anni della Clinica Mangiagalli: celebriamo la culla d’Italiahttps://www.pharmaradar360.com/article/puma-biotechnology-nasdaq-pbyi-director-exercises-50k-options-sells-62k-shares-4587cf2f7f1ab95bPharmaRadar360en2026-09-17T01:13:06.000ZPuma Biotechnology (NASDAQ: PBYI) director exercises 50K options, sells 62K shareshttps://www.pharmaradar360.com/article/working-with-emotional-intelligence-in-the-pharmaceutical-and-biopharma-industry-8a25c40b31642bddPharmaRadar360en2026-09-17T01:01:51.000ZWorking with Emotional Intelligence in the Pharmaceutical and Biopharma Industry Training Course Scheduled for October 19, 2026https://www.pharmaradar360.com/article/menicon-to-support-the-protection-of-japanese-crested-ibis-habitats-for-the-16th-b696997410e8a3c4PharmaRadar360en2026-09-17T01:00:00.000ZMenicon to support the protection of Japanese crested ibis habitats for the 16th consecutive year through its rice farming businesshttps://www.pharmaradar360.com/article/about-teva-pharmaceutical-industries-ltd-rstock-cc93b96ead8637d1PharmaRadar360en2026-09-17T00:57:40.000ZAbout Teva Pharmaceutical Industries Ltd. rStockhttps://www.pharmaradar360.com/article/greater-access-to-help-needed-for-women-with-nausea-during-pregnancy-44936c86b6095aaaPharmaRadar360en2026-09-17T00:42:44.000ZGreater access to help needed for women with nausea during pregnancyhttps://www.pharmaradar360.com/article/bytedance-spin-off-ai-pharmaceutical-division-secures-massive-2-billion-yuan-fir-e94c7127fad69d8aPharmaRadar360en2026-09-17T00:30:48.000ZByteDance Spin-off AI Pharmaceutical Division Secures Massive 2 Billion Yuan First-Round Financinghttps://www.pharmaradar360.com/article/la-unlp-busca-actualizar-el-sistema-de-boleto-educativo-gratuito-bb1a8f9c105b87b5PharmaRadar360en2026-09-17T00:18:59.000ZLa UNLP busca actualizar el sistema de Boleto Educativo Gratuitohttps://www.pharmaradar360.com/article/a-50-anos-de-su-asesinato-rendimos-homenaje-a-sergio-karakachoff-c0d9a09f2a74861fPharmaRadar360en2026-09-17T00:18:28.000ZA 50 años de su asesinato, rendimos homenaje a Sergio Karakachoffhttps://www.pharmaradar360.com/article/krystal-biotech-krys-board-member-receives-new-options-and-rsus-0fda544b57675dd6PharmaRadar360en2026-09-17T00:07:13.000ZKrystal Biotech (KRYS) board member receives new options and RSUshttps://www.pharmaradar360.com/article/sanofi-filed-form-6-k-d667b90b40c7dbc4PharmaRadar360en2026-09-17T00:00:00.000ZSanofi filed Form 6-Khttps://www.pharmaradar360.com/article/levetiracetam-therapeutically-targets-gabaergic-synapses-in-diffuse-midline-glio-5521cb0cfbf33f83PharmaRadar360en2026-09-17T00:00:00.000ZLevetiracetam therapeutically targets GABAergic synapses in diffuse midline gliomahttps://www.pharmaradar360.com/article/gene-editing-using-large-insertions-b56e263edfad4029PharmaRadar360en2026-09-17T00:00:00.000ZGene editing using large insertionshttps://www.pharmaradar360.com/article/openai-maths-bombshell-sparks-debate-about-who-gets-credit-in-age-of-ai-525b07c63b1d5c27PharmaRadar360en2026-09-17T00:00:00.000ZOpenAI maths bombshell sparks debate about who gets credit in age of AIhttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-17c3d45d22923d82PharmaRadar360en2026-09-17T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9794-4-crore-consolidated-revenue-and-e2-82-b9206-5-crore-o-66b0f20b86c2255cPharmaRadar360en2026-09-17T00:00:00.000Znatco records %e2%82%b9794 4 crore consolidated revenue and %e2%82%b9206 5 crore of profit after tax for q1 fy27https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-4a59b1c2ed733d19PharmaRadar360en2026-09-17T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-4378e1c358b339d2PharmaRadar360en2026-09-17T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-5d81ec75d698a18bPharmaRadar360en2026-09-17T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-570e3923de0665e2PharmaRadar360en2026-09-17T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-0b3e234afc04713fPharmaRadar360en2026-09-17T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-dcf73b30774018ccPharmaRadar360en2026-09-17T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-limited-announces-conclusion-of-us-fda-inspection-at-visakhapatnam-10425e7183db5dd5PharmaRadar360en2026-09-17T00:00:00.000Znatco pharma limited announces conclusion of us fda inspection at visakhapatnam andhra pradesh finished dosage formulations fdf unithttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-39d68e08ac00ac5bPharmaRadar360en2026-09-17T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-6da2da2fcc1fb29bPharmaRadar360en2026-09-17T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-11af9de2ede1fd40PharmaRadar360en2026-09-17T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/investment-of-us-14-million-in-egenesis-inc-by-natco-pharma-canada-inc-and-natco-0e39ac934cc7410bPharmaRadar360en2026-09-17T00:00:00.000Zinvestment of us 14 million in egenesis inc by natco pharma canada inc and natco pharma south africa proprietary limitedhttps://www.pharmaradar360.com/article/home-page-77d73423ceb71d77PharmaRadar360en2026-09-17T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/recommendations-for-the-development-of-blood-collection-processing-and-storage-s-b8c6b7db48c7e21ePharmaRadar360en2026-09-17T00:00:00.000ZRecommendations for the Development of Blood Collection, Processing, and Storage Systems for the Manufacture of Blood Components Using the Buffy Coat Method; Guidance for Industry; Availabilityhttps://www.pharmaradar360.com/article/agency-information-collection-activities-proposed-collection-comment-request-e6707987ea0046b9PharmaRadar360en2026-09-17T00:00:00.000ZAgency Information Collection Activities: Proposed Collection; Comment Requesthttps://www.pharmaradar360.com/article/medical-devices-exemption-from-premarket-notification-radiology-computer-aided-d-1da78c63c52f8524PharmaRadar360en2026-09-17T00:00:00.000ZMedical Devices; Exemption From Premarket Notification: Radiology Computer-Aided Detection and/or Diagnosis Devices and Computer-Aided Triage and Notification Deviceshttps://www.pharmaradar360.com/article/medicare-and-medicaid-programs-application-from-dnv-healthcare-usa-inc-dnv-for-c-44f3c570867b78f3PharmaRadar360en2026-09-17T00:00:00.000ZMedicare and Medicaid Programs; Application From DNV Healthcare USA Inc. (DNV) for Continued CMS-Approval of its Hospital Accreditation Programhttps://www.pharmaradar360.com/article/proposed-information-collection-activity-diaper-distribution-demonstration-and-r-2a2324bd5db6fe4bPharmaRadar360en2026-09-17T00:00:00.000ZProposed Information Collection Activity; Diaper Distribution Demonstration and Research Pilot Beneficiary and Organizational Survey and Beneficiary Reporthttps://www.pharmaradar360.com/article/undersoker-sambanden-mellan-sociala-villkor-och-psykisk-ohalsa-9c4a5c6e43587264PharmaRadar360en2026-09-17T00:00:00.000ZUndersöker sambanden mellan sociala villkor och psykisk ohälsahttps://www.pharmaradar360.com/article/brister-i-var-tredje-journal-vid-utredning-av-mojliga-cancersymtom-34d21f33f335d0a7PharmaRadar360en2026-09-17T00:00:00.000ZBrister i var tredje journal vid utredning av möjliga cancersymtomhttps://www.pharmaradar360.com/article/bengt-fadeel-keynote-talare-vid-eurotox-2026-2f5972eb8e18c29aPharmaRadar360en2026-09-17T00:00:00.000ZBengt Fadeel Keynote Talare vid EUROTOX 2026https://www.pharmaradar360.com/article/author-response-screening-the-mmv-pathogen-box-reveals-the-mitochondrial-bc1-com-10cec4bb4b7e08bcPharmaRadar360en2026-09-17T00:00:00.000ZAuthor response: Screening the MMV Pathogen Box reveals the mitochondrial bc1-complex as a drug target in mature Toxoplasma gondii bradyzoiteshttps://www.pharmaradar360.com/article/screening-the-mmv-pathogen-box-reveals-the-mitochondrial-bc1-complex-as-a-drug-t-17cf47f0595fc2f2PharmaRadar360en2026-09-17T00:00:00.000ZScreening the MMV Pathogen Box reveals the mitochondrial bc1-complex as a drug target in mature Toxoplasma gondii bradyzoiteshttps://www.pharmaradar360.com/article/respuesta-clinica-y-predictores-de-mortalidad-en-pacientes-con-ventilacion-mecan-bad3f71736007fb9PharmaRadar360en2026-09-17T00:00:00.000ZRespuesta clínica y predictores de mortalidad en pacientes con ventilación mecánica no invasiva en un servicio de urgencias: estudio observacionalhttps://www.pharmaradar360.com/article/routine-immediate-postoperative-chest-radiography-after-minimally-invasive-pulmo-4aa500f12b8a1c92PharmaRadar360en2026-09-17T00:00:00.000ZRoutine Immediate Postoperative Chest Radiography After Minimally Invasive Pulmonary Lobectomy Has a Low Impact on Clinical Management: A Value-Based Imaging Analysishttps://www.pharmaradar360.com/article/non-systemic-oral-cellulose-based-superabsorbent-hydrogels-for-weight-management-1e7367eb1f656e51PharmaRadar360en2026-09-17T00:00:00.000ZNon-Systemic Oral Cellulose-Based Superabsorbent Hydrogels for Weight Management: Potential Drug-Device Interactions Estimated by a Simplified In Vitro Assayhttps://www.pharmaradar360.com/article/perioperative-and-mid-term-outcomes-of-primary-versus-redo-pericardiectomy-for-c-1a635c7aa54495a5PharmaRadar360en2026-09-17T00:00:00.000ZPerioperative and Mid-Term Outcomes of Primary Versus Redo Pericardiectomy for Constrictive Pericarditis: A Single-Center Retrospective Cohort Studyhttps://www.pharmaradar360.com/article/long-term-prosthesis-survival-after-total-hip-arthroplasty-in-young-women-with-d-319dd339550173cfPharmaRadar360en2026-09-17T00:00:00.000ZLong-Term Prosthesis Survival After Total Hip Arthroplasty in Young Women with Developmental Dysplasia of the Hip: A Narrative Review of Instability, Revision Risk, and Reproductive Health Considerationshttps://www.pharmaradar360.com/article/spectrum-of-hereditary-ataxia-in-omani-children-46c98951ca8fdde4PharmaRadar360en2026-09-17T00:00:00.000ZSpectrum of Hereditary Ataxia in Omani Childrenhttps://www.pharmaradar360.com/article/incidental-misdiagnosed-intrahepatic-cholangiocarcinoma-and-combined-hepatocellu-c0bd4395c613f23dPharmaRadar360en2026-09-17T00:00:00.000ZIncidental/Misdiagnosed Intrahepatic Cholangiocarcinoma and Combined Hepatocellular-Cholangiocarcinoma in Patients Undergoing Living Donor Liver Transplantationhttps://www.pharmaradar360.com/article/can-diagnostic-delay-amplify-drug-resistance-in-tuberculosis-a-critical-integrat-e8ff8bb311e6bad4PharmaRadar360en2026-09-17T00:00:00.000ZCan Diagnostic Delay Amplify Drug Resistance in Tuberculosis? A Critical Integrative Reflection on Bacterial Adaptation, Persistence, Within-Host Evolution, and Heteroresistancehttps://www.pharmaradar360.com/article/clinical-and-radiological-characteristics-of-pediatric-skull-fractures-and-their-ab36bd523cdbec99PharmaRadar360en2026-09-17T00:00:00.000ZClinical and Radiological Characteristics of Pediatric Skull Fractures and Their Association with Neurosurgical Intervention: A Retrospective Cohort Studyhttps://www.pharmaradar360.com/article/organoboronic-acids-as-co-formers-in-pharmaceutical-crystal-engineering-d4e373881148a581PharmaRadar360en2026-09-17T00:00:00.000ZOrganoboronic Acids as Co-Formers in Pharmaceutical Crystal Engineeringhttps://www.pharmaradar360.com/article/interventions-to-reduce-antibiotic-prescribing-in-small-animal-veterinary-practi-4006c75ca92b7120PharmaRadar360en2026-09-17T00:00:00.000ZInterventions to Reduce Antibiotic Prescribing in Small Animal Veterinary Practice: Evidence and Clinical Impacthttps://www.pharmaradar360.com/article/promater-protocol-for-a-randomized-controlled-trial-of-a-digital-self-guided-int-c7b2846433ae325fPharmaRadar360en2026-09-17T00:00:00.000ZPROMATER: protocol for a randomized controlled trial of a digital self-guided intervention to promote perinatal mental health and reduce self-criticismhttps://www.pharmaradar360.com/article/ai-enabled-passive-digital-phenotyping-of-experiential-negative-symptoms-in-schi-9e28b9b0c36b8694PharmaRadar360en2026-09-17T00:00:00.000ZAI-enabled passive digital phenotyping of experiential negative symptoms in schizophrenia-spectrum disorders: a narrative review on the path from sensing to clinical endpointshttps://www.pharmaradar360.com/article/waveband-resolved-nonlinear-characterization-of-serf-magnetocardiography-signals-edca74eb526ec354PharmaRadar360en2026-09-17T00:00:00.000ZWaveband-resolved nonlinear characterization of SERF-magnetocardiography signals: a phase-space reconstruction framework for exploratory clinical cohort analysishttps://www.pharmaradar360.com/article/editorial-volume-ii-tumour-microenvironment-in-cancer-research-and-drug-discover-7fe50959d7c1a534PharmaRadar360en2026-09-17T00:00:00.000ZEditorial: Volume II: tumour microenvironment in cancer research and drug discoveryhttps://www.pharmaradar360.com/article/clinical-value-of-probiotics-as-adjunctive-therapy-for-diabetic-nephropathy-a-me-13c9984fdb8213cdPharmaRadar360en2026-09-17T00:00:00.000ZClinical value of probiotics as adjunctive therapy for diabetic nephropathy: a meta-analysis and trial sequential analysishttps://www.pharmaradar360.com/article/global-research-trends-in-tuberculosis-drug-resistance-mechanisms-a-bibliometric-a1b5946382edc9ebPharmaRadar360en2026-09-17T00:00:00.000ZGlobal research trends in tuberculosis drug-resistance mechanisms: a bibliometric and cross-database analysishttps://www.pharmaradar360.com/article/off-target-drug-repurposing-for-rare-and-ultra-rare-cancers-towards-a-scalable-t-049d863795cd2bcaPharmaRadar360en2026-09-17T00:00:00.000ZOff-target drug repurposing for rare and ultra-rare cancers: towards a scalable therapeutic frameworkhttps://www.pharmaradar360.com/article/an-integrated-tam-aida-model-for-digital-health-technology-adoption-evidence-fro-27a9d20c4f65a064PharmaRadar360en2026-09-17T00:00:00.000ZAn Integrated TAM–AIDA Model for Digital Health Technology Adoption: Evidence from a Pandemic-Informed Quantitative Studyhttps://www.pharmaradar360.com/article/risk-factors-and-short-term-outcomes-of-lower-limb-fractures-in-diabetic-patient-08bb6d6c5ead5d38PharmaRadar360en2026-09-17T00:00:00.000ZRisk Factors and Short-Term Outcomes of Lower Limb Fractures in Diabetic Patients Presenting to Emergencyhttps://www.pharmaradar360.com/article/pharmacological-impact-of-mydriatic-drops-on-intraocular-pressure-variations-acr-21669ad105ec4b61PharmaRadar360en2026-09-17T00:00:00.000ZPharmacological Impact of Mydriatic Drops on Intraocular Pressure: Variations across Different Phakic Status and Demographic Groupshttps://www.pharmaradar360.com/article/unraveling-the-mystery-of-status-epilepticus-a-retrospective-study-at-a-tertiary-a9048ab8cd680ff1PharmaRadar360en2026-09-17T00:00:00.000ZUnraveling the mystery of status epilepticus: a retrospective study at a tertiary care centre from Indiahttps://www.pharmaradar360.com/article/microplastic-exposure-in-everyday-life-an-awareness-based-kap-study-among-the-in-46559a8bb0d2738fPharmaRadar360en2026-09-17T00:00:00.000ZMicroplastic Exposure in Everyday Life: An Awareness-Based KAP Study Among the Indian Populationhttps://www.pharmaradar360.com/article/impact-of-simulated-long-term-brushing-and-acid-exposure-on-the-surface-properti-202a2db61a3f0909PharmaRadar360en2026-09-17T00:00:00.000ZImpact of simulated long-term brushing and acid exposure on the surface properties of pit-and-fissure sealants: an in vitro studyhttps://www.pharmaradar360.com/article/clinical-profile-of-primary-headache-disorders-in-patients-with-epilepsy-and-res-b4e9273ab4be4795PharmaRadar360en2026-09-17T00:00:00.000ZClinical Profile of Primary Headache Disorders in Patients with Epilepsy and Response to Standard-of-Care Migraine Preventive Treatment: A South Asian Cohorthttps://www.pharmaradar360.com/article/clinical-predictors-of-early-multidomain-symptomatic-recovery-in-hospitalized-pa-35b55f37f9e3dce4PharmaRadar360en2026-09-17T00:00:00.000ZClinical predictors of early multidomain symptomatic recovery in hospitalized patients with chronic lung disease and post-COVID conditions: a secondary analysis of a prospective controlled cohorthttps://www.pharmaradar360.com/article/a-clinical-study-on-multidimensional-phenotypic-parameters-of-gender-and-age-dif-98810244e0a54730PharmaRadar360en2026-09-17T00:00:00.000ZA clinical study on multidimensional phenotypic parameters of gender and age differences between Chinese dry mouth and non-dry mouth populationhttps://www.pharmaradar360.com/article/mind-over-cervix-using-virtual-reality-to-improve-anxiety-and-pain-during-outpat-f47ec1626d949d07PharmaRadar360en2026-09-17T00:00:00.000ZMind Over Cervix: Using virtual reality to improve anxiety and pain during outpatient colposcopy – a randomised controlled trialhttps://www.pharmaradar360.com/article/effects-of-preoperative-coenzyme-q10-supplementation-on-oxidative-stress-and-wou-74761ebb3a19b789PharmaRadar360en2026-09-17T00:00:00.000ZEffects of Preoperative Coenzyme Q10 Supplementation on Oxidative Stress and Wound Healing Following Orthognathic Surgery: A Randomized Placebo-Controlled Trialhttps://www.pharmaradar360.com/article/anatomical-features-and-hemodynamic-aspects-of-vascular-anastomoses-in-reconstru-5267a214891b3b54PharmaRadar360en2026-09-17T00:00:00.000ZAnatomical features and hemodynamic aspects of vascular anastomoses in reconstructive cardiovascular surgeryhttps://www.pharmaradar360.com/article/to-eat-or-not-to-eat-dietary-patterns-and-the-clinical-recognition-of-insulinoma-77c4e9d24c7b9904PharmaRadar360en2026-09-17T00:00:00.000ZTo eat, or not to eat… dietary patterns and the clinical recognition of insulinoma: a case reporthttps://www.pharmaradar360.com/article/hypercholesterolemia-in-underweight-individuals-mechanisms-clinical-significance-f5008e8cc58ce6a6PharmaRadar360en2026-09-17T00:00:00.000ZHypercholesterolemia in Underweight Individuals: Mechanisms, Clinical Significance and Practical Recommendationshttps://www.pharmaradar360.com/article/nasopharyngeal-carcinoma-epidemiology-risk-factors-signaling-pathways-clinical-f-9be3d020f20b2d04PharmaRadar360en2026-09-17T00:00:00.000ZNasopharyngeal carcinoma: epidemiology, risk factors, signaling pathways, clinical features, diagnosis, and managementhttps://www.pharmaradar360.com/article/assessment-of-clinical-education-assce-a-scoping-review-of-use-and-experiences-o-3e91b28930af36caPharmaRadar360en2026-09-17T00:00:00.000ZAssessment of clinical education (ASSCE): a scoping review of use and experiences of the toolhttps://www.pharmaradar360.com/article/express-longitudinal-circulating-mirna-profiling-identifies-pharmacodynamic-biom-b4eccbcf06de3c8ePharmaRadar360en2026-09-17T00:00:00.000ZEXPRESS: Longitudinal Circulating miRNA Profiling Identifies Pharmacodynamic Biomarkers of Remote Ischemic Conditioning in Acute Ischemic Stroke: A Translational Sub-Study of the Randomized TRICS-9 Trialhttps://www.pharmaradar360.com/article/women-s-kidney-health-in-focus-a-scientific-statement-from-the-american-heart-as-528fafe1392aeedcPharmaRadar360en2026-09-17T00:00:00.000ZWomen’s Kidney Health in Focus: A Scientific Statement From the American Heart Associationhttps://www.pharmaradar360.com/article/local-and-systemic-risk-factors-of-dental-biofilm-induced-gingivitis-and-their-c-3aa6ba93a69d0a95PharmaRadar360en2026-09-17T00:00:00.000ZLocal and Systemic Risk Factors of Dental Biofilm‐Induced Gingivitis and Their Control: A Systematic Reviewhttps://www.pharmaradar360.com/article/predicting-the-long-term-risk-of-type-2-diabetes-and-cardiovascular-disease-with-278ebe7d9c1b0a9ePharmaRadar360en2026-09-17T00:00:00.000ZPredicting the Long‐Term Risk of Type 2 Diabetes and Cardiovascular Disease With Orforglipron in People With Overweight or Obesity: A Post Hoc Analysis of the <scp>ATTAIN</scp> ‐1 Trialhttps://www.pharmaradar360.com/article/neurofeedback-for-functional-neurological-disorders-future-directions-for-resear-9f18be548ab7c6f8PharmaRadar360en2026-09-17T00:00:00.000ZNeurofeedback for functional neurological disorders: future directions for research and clinical practicehttps://www.pharmaradar360.com/article/water-and-liquid-soap-cleaning-of-removable-orthodontic-appliances-a-triple-blin-f4be5b10c5e36833PharmaRadar360en2026-09-17T00:00:00.000ZWater and Liquid Soap Cleaning of Removable Orthodontic Appliances: A Triple‑Blind Randomized Crossover Study of Microbial Load Reductionhttps://www.pharmaradar360.com/article/clinical-and-microbiologic-predictors-of-progression-to-infection-among-children-981a1a8b318f2fc1PharmaRadar360en2026-09-17T00:00:00.000ZClinical and Microbiologic Predictors of Progression to Infection Among Children With Enteric Colonization by Carbapenemase-producing Enterobacteraleshttps://www.pharmaradar360.com/article/development-and-internal-validation-of-an-ehr-machine-learning-model-for-clinica-f6dc3fc0d96a01f1PharmaRadar360en2026-09-17T00:00:00.000ZDevelopment and internal validation of an EHR machine learning model for clinical deterioration in ICU linked inpatientshttps://www.pharmaradar360.com/article/effects-of-a-three-month-exercise-programme-on-cognition-mood-and-neurogenesis-t-d2be6075925e41ccPharmaRadar360en2026-09-17T00:00:00.000ZEffects of a three-month exercise programme on cognition, mood and neurogenesis: the NeuroFit randomised controlled trialhttps://www.pharmaradar360.com/article/harnessing-endogenous-carbon-monoxide-for-cancer-selective-drug-synthesis-23780c69301d10a7PharmaRadar360en2026-09-17T00:00:00.000ZHarnessing endogenous carbon monoxide for cancer-selective drug synthesishttps://www.pharmaradar360.com/article/modulating-the-periodontal-wound-microenvironment-through-oxygen-therapy-a-narra-c1466eabbd8e63abPharmaRadar360en2026-09-17T00:00:00.000ZModulating the periodontal wound microenvironment through oxygen therapy: a narrative review on the biological basis, clinical applications and future perspectiveshttps://www.pharmaradar360.com/article/the-dual-role-of-cholesterol-metabolism-in-hepatocellular-carcinoma-mechanisms-t-52c334fe86bb524bPharmaRadar360en2026-09-17T00:00:00.000ZThe Dual Role of Cholesterol Metabolism in Hepatocellular Carcinoma: Mechanisms, Therapeutic Strategies and Future Perspectiveshttps://www.pharmaradar360.com/article/interpreting-positive-and-inverse-disproportionality-signals-in-spontaneous-repo-1200b13c43ca8e4cPharmaRadar360en2026-09-17T00:00:00.000ZInterpreting Positive and Inverse Disproportionality Signals in Spontaneous Reporting Systems: A Claim-Strength Framework with Direction-Aware Evaluationhttps://www.pharmaradar360.com/article/glucagon-like-peptide-1-receptor-agonists-and-neovascular-age-related-macular-de-525d52014b3f883cPharmaRadar360en2026-09-17T00:00:00.000ZGlucagon-Like Peptide-1 Receptor Agonists and Neovascular Age-Related Macular Degeneration in Type 2 Diabetes: A Review of Emerging Clinical Evidencehttps://www.pharmaradar360.com/article/sub-acute-clinical-leaflet-thrombosis-after-transcatheter-aortic-valve-implantat-c4a7c6391d426847PharmaRadar360en2026-09-17T00:00:00.000ZSub-acute clinical leaflet thrombosis after transcatheter aortic valve implantation under direct oral anticoagulantshttps://www.pharmaradar360.com/article/efficacy-of-buffered-vs-non-buffered-4-articaine-local-anaesthetic-solution-in-a-4ab465f7d4e61830PharmaRadar360en2026-09-17T00:00:00.000ZEfficacy of Buffered vs. Non–buffered 4% Articaine Local Anaesthetic Solution in Abscessed Tooth: An Interventional Comparative Double Blind Clinical Studyhttps://www.pharmaradar360.com/article/surgical-resection-of-a-liver-metastasis-from-an-ovarian-granulosa-cell-tumor-mi-72fc1923a67b60b6PharmaRadar360en2026-09-17T00:00:00.000ZSurgical resection of a liver metastasis from an ovarian granulosa cell tumor mimicking a simple hepatic cysthttps://www.pharmaradar360.com/article/in-silico-and-hansen-solubility-parameters-guided-hme-3d-printed-tablets-boostin-30492068315baa08PharmaRadar360en2026-09-17T00:00:00.000ZIn Silico and Hansen Solubility Parameters-Guided HME-3D Printed Tablets: Boosting Aceclofenac Solubility and Dissolutionhttps://www.pharmaradar360.com/article/pharmaceutical-import-forecasting-for-supply-chain-decision-support-a-comparativ-1fbb7af35c0e9d08PharmaRadar360en2026-09-17T00:00:00.000ZPharmaceutical Import Forecasting for Supply-Chain Decision Support: A Comparative Evaluation of Fuzzy, Statistical, and Machine-Learning Modelshttps://www.pharmaradar360.com/article/in-vitro-anti-inflammatory-evaluation-gene-expression-hr-lc-ms-profiling-and-in-3d700e8cd593a619PharmaRadar360en2026-09-17T00:00:00.000ZIn Vitro Anti-Inflammatory Evaluation, Gene Expression, HR-LC–MS Profiling, and in silico Molecular Docking of Active Fraction from Rauvolfia densiflora Benth. ex Hook.f. (Apocynaceae)https://www.pharmaradar360.com/article/the-agroenvironmental-clinical-link-of-proteus-mirabilis-genomic-epidemiology-cl-b5598d5aee03a1b2PharmaRadar360en2026-09-17T00:00:00.000ZThe agroenvironmental-clinical link of Proteus mirabilis: Genomic epidemiology, clonal relationships, and shared resistance and virulence profileshttps://www.pharmaradar360.com/article/clinical-utility-of-magnetic-resonance-enterography-for-pediatric-crohn-s-diseas-87bd48bb81c7cd25PharmaRadar360en2026-09-17T00:00:00.000ZClinical utility of magnetic resonance enterography for pediatric Crohn’s disease: a review with illustrative cases and a focus on Japanhttps://www.pharmaradar360.com/article/design-development-and-optimisation-of-an-amorphous-solid-dispersion-based-etori-91b0613d64d9403ePharmaRadar360en2026-09-17T00:00:00.000ZDesign, development, and optimisation of an amorphous solid dispersion-based etoricoxib bigel for targeted topical anti-inflammatory drug deliveryhttps://www.pharmaradar360.com/article/early-clinical-mediation-in-end-of-life-disputes-a-procedural-justice-analysis-bd4d4e19235b69dfPharmaRadar360en2026-09-17T00:00:00.000ZEarly Clinical Mediation in End-of-Life Disputes: A Procedural Justice Analysishttps://www.pharmaradar360.com/article/astellas-announces-personnel-change-956652823d3f43cdPharmaRadar360en2026-09-16T23:30:00.000ZAstellas Announces Personnel Changehttps://www.pharmaradar360.com/article/teva-s-lab-made-antibody-shot-for-celiac-shows-hopeful-results-ecbc01d07dffb77cPharmaRadar360en2026-09-16T22:36:14.000ZTeva’s Lab-Made Antibody Shot for Celiac Shows Hopeful Resultshttps://www.pharmaradar360.com/article/pedro-resources-takes-250k-bridge-loan-from-insiders-as-it-eyes-biotech-pivot-9861b7f2fe548a26PharmaRadar360en2026-09-16T22:09:13.000ZPedro Resources takes $250K bridge loan from insiders as it eyes biotech pivothttps://www.pharmaradar360.com/article/uc-irvine-receives-4-2-million-nih-award-to-continue-all-of-us-enrollment-883c35c953fde48cPharmaRadar360en2026-09-16T22:05:29.000Z​UC Irvine receives $4.2 million NIH award to continue All of Us enrollmenthttps://www.pharmaradar360.com/article/passaparola-21-09-e-23-09-controlli-gratuiti-per-prevenire-i-tumori-testa-collo-b253ae8838f5ca92PharmaRadar360en2026-09-16T21:59:00.000Z#PASSAPAROLA [21.09 e 23.09] Controlli gratuiti per prevenire i tumori-testa collohttps://www.pharmaradar360.com/article/convegno-21-09-fattori-di-rischio-e-differenti-scenari-nella-masld-una-sfida-quo-9b5ebdf1cefe3ce4PharmaRadar360en2026-09-16T21:59:00.000Z#CONVEGNO [21.09] Fattori di rischio e differenti scenari nella MASLD. Una sfida quotidiana per l'internista - Gratuito con crediti ECMhttps://www.pharmaradar360.com/article/food-biotech-s-us-75-000-second-life-23b198dbdacbdaefPharmaRadar360en2026-09-16T21:58:59.000ZFood Biotech’s US$75,000 Second Lifehttps://www.pharmaradar360.com/article/iconthin-biotech-marks-10-years-of-microalgae-innovation-as-astadaily-expands-ca-b776a2d708fd1090PharmaRadar360en2026-09-16T21:45:04.000ZIconthin Biotech Marks 10 Years of Microalgae Innovation as Astadaily Expands Canadian Retail Presencehttps://www.pharmaradar360.com/article/amgen-hit-with-lawsuit-over-its-proposed-opdivo-biosimilar-1f2484de4e80d755PharmaRadar360en2026-09-16T21:23:47.000ZAmgen hit with lawsuit over its proposed Opdivo biosimilarhttps://www.pharmaradar360.com/article/2026-ipo-stock-tracker-how-newly-public-biotechs-are-performing-077ec10ed091a6c5PharmaRadar360en2026-09-16T21:10:35.000Z2026 IPO stock tracker: How newly public biotechs are performinghttps://www.pharmaradar360.com/article/etfs-investing-in-zhejiang-anglikang-pharmaceutical-co-ltd-class-a-stocks-0cba90adc2365995PharmaRadar360en2026-09-16T20:53:47.000ZETFs Investing in Zhejiang Anglikang Pharmaceutical Co. Ltd. Class A Stockshttps://www.pharmaradar360.com/article/teva-pharmaceutical-finance-netherlands-ii-issues-eur-1-bln-of-4-250-senior-note-0f9644fe8abe7fc0PharmaRadar360en2026-09-16T20:39:26.000ZTeva Pharmaceutical Finance Netherlands II Issues EUR 1 Bln Of 4.250% Senior Notes Due 2033https://www.pharmaradar360.com/article/ada-family-day-at-the-dallas-zoo-d802a9e5bea6be67PharmaRadar360en2026-09-16T20:29:22.000ZADA Family Day at the Dallas Zoohttps://www.pharmaradar360.com/article/why-this-biotech-stock-just-got-a-rare-double-upgrade-7e7dcd156623785dPharmaRadar360en2026-09-16T20:25:00.000ZWhy This Biotech Stock Just Got a Rare Double Upgradehttps://www.pharmaradar360.com/article/ufrj-comemora-20-anos-do-curso-de-biblioteconomia-e-gestao-de-unidades-de-inform-aa541f68d0cecdb6PharmaRadar360en2026-09-16T20:18:59.000ZUFRJ comemora 20 anos do curso de Biblioteconomia e Gestão de Unidades de Informação do campus Praia Vermelhahttps://www.pharmaradar360.com/article/telix-pharmaceuticals-buy-on-pixclara-fda-approval-and-tlx591-tx-part-2-advancem-e547720d3a6557d1PharmaRadar360en2026-09-16T20:10:10.000ZTelix Pharmaceuticals: 'Buy' On Pixclara FDA Approval And TLX591-Tx Part 2 Advancementhttps://www.pharmaradar360.com/article/3-tar-heel-army-rotc-cadets-earn-recondo-badge-baaf02bcf6b204edPharmaRadar360en2026-09-16T20:00:34.000Z3 Tar Heel Army ROTC cadets earn RECONDO badgehttps://www.pharmaradar360.com/article/a-75-million-payment-is-triggered-as-innate-pharma-starts-a-cancer-trial-81224f5f9fdca6c4PharmaRadar360en2026-09-16T20:00:00.000ZA $75 million payment is triggered as Innate Pharma starts a cancer trialhttps://www.pharmaradar360.com/article/ers-2026-obesity-an-independent-obstruction-to-biologic-treated-asthma-8fe9aca8139f27b2PharmaRadar360en2026-09-16T19:56:00.000ZERS 2026: obesity, an independent obstruction to biologic-treated asthmahttps://www.pharmaradar360.com/article/uc-irvine-researchers-to-establish-countywide-effort-to-catch-early-warning-sign-310e63d12e70c99bPharmaRadar360en2026-09-16T19:35:12.000ZUC Irvine researchers to establish countywide effort to catch early warning signshttps://www.pharmaradar360.com/article/breakthrough-study-finds-possible-causes-of-cardiac-fibrosis-in-hlhs-fb08546c24883418PharmaRadar360en2026-09-16T19:28:58.000ZBreakthrough study finds possible causes of cardiac fibrosis in HLHShttps://www.pharmaradar360.com/article/intermountain-health-saint-joseph-hospital-earns-magnet-recognition-with-distinc-1c8ca357cdfc66c9PharmaRadar360en2026-09-16T19:18:17.000ZIntermountain Health Saint Joseph Hospital Earns Magnet Recognition with Distinctionhttps://www.pharmaradar360.com/article/sling-ropes-in-123m-for-oral-thyroid-eye-disease-drug-545cdd139d817376PharmaRadar360en2026-09-16T19:11:46.000ZSling ropes in $123m for oral thyroid eye disease drughttps://www.pharmaradar360.com/article/mayer-brown-represents-underwriters-on-teva-pharmaceutical-s-us-4-9-billion-seni-3890078c3ce9091aPharmaRadar360en2026-09-16T19:09:08.000ZMayer Brown represents underwriters on Teva Pharmaceutical’s US$4.9 billion senior notes offeringhttps://www.pharmaradar360.com/article/intermountain-health-good-samaritan-hospital-introduces-ladies-night-out-f12b373d9531245fPharmaRadar360en2026-09-16T18:58:52.000ZIntermountain Health Good Samaritan Hospital Introduces Ladies’ Night Outhttps://www.pharmaradar360.com/article/thanks-trump-why-canada-may-become-the-european-union-s-first-ever-associate-mem-159cd5ace0912083PharmaRadar360en2026-09-16T18:56:04.000ZThanks, Trump: Why Canada may become the European Union’s first ever ‘associate member’https://www.pharmaradar360.com/article/novartis-gains-a-way-to-get-drugs-into-the-brain-buying-sironax-tech-for-125m-29a20728c63ef2a3PharmaRadar360en2026-09-16T18:35:03.000ZNovartis Gains a Way to Get Drugs Into the Brain, Buying Sironax Tech for $125Mhttps://www.pharmaradar360.com/article/kemri-kagoshima-university-explore-new-areas-for-research-and-training-collabora-7f84458cdc414908PharmaRadar360en2026-09-16T18:24:24.000ZKEMRI, Kagoshima University Explore New Areas for Research and Training Collaborationhttps://www.pharmaradar360.com/article/fda-approves-first-ever-drug-to-treat-life-threatening-disease-a-landmark-moment-47b6edd63729a568PharmaRadar360en2026-09-16T18:20:00.000ZFDA approves first-ever drug to treat life-threatening disease: ‘A landmark moment’https://www.pharmaradar360.com/article/kemri-rafiki-holds-a-workshop-to-advance-drug-discovery-and-development-in-afric-6ae1b0a8fe5e9c37PharmaRadar360en2026-09-16T18:14:06.000ZKEMRI-RAFIKI Holds A Workshop to Advance Drug Discovery and Development in Africahttps://www.pharmaradar360.com/article/anmat-fortalecio-la-cooperacion-regulatoria-regional-en-la-reunion-anual-latinoa-a27b9b1eefa3aeaaPharmaRadar360en2026-09-16T18:07:34.000ZANMAT fortaleció la cooperación regulatoria regional en la Reunión Anual Latinoamericana de DIA 2026 en la Ciudad de Méxicohttps://www.pharmaradar360.com/article/the-car-in-your-garage-can-power-your-house-66c17fe910c507abPharmaRadar360en2026-09-16T18:04:54.000ZThe car in your garage can power your househttps://www.pharmaradar360.com/article/celebrate-university-day-at-the-bell-tower-at-night-178b10df9de9e5e2PharmaRadar360en2026-09-16T17:53:40.000ZCelebrate University Day at the Bell Tower — at nighthttps://www.pharmaradar360.com/article/pharma-pulse-behind-the-scenes-of-logipharma-usa-2026-d71d1ef69cd0003aPharmaRadar360en2026-09-16T17:43:37.000ZPharma Pulse: Behind the Scenes of LogiPharma USA 2026https://www.pharmaradar360.com/article/kemri-and-partners-launch-handbook-to-strengthen-suicide-prevention-088712614b0aebedPharmaRadar360en2026-09-16T17:38:24.000ZKEMRI and Partners Launch Handbook to Strengthen Suicide Preventionhttps://www.pharmaradar360.com/article/looking-beyond-short-term-turmoil-syngene-is-investing-for-the-future-ff2542fffd1088f1PharmaRadar360en2026-09-16T17:28:56.000ZLooking beyond short-term turmoil, Syngene is investing for the futurehttps://www.pharmaradar360.com/article/the-nih-funding-crisis-that-could-reshape-biotech-for-years-to-come-b62b5f7bdd7a60dePharmaRadar360en2026-09-16T17:21:29.000ZThe NIH funding crisis that could reshape biotech for years to comehttps://www.pharmaradar360.com/article/vivosim-labs-vivs-fda-approvals-pdufa-dates-drug-alerts-2026-vivs-9890ddb010a5431bPharmaRadar360en2026-09-16T17:18:54.000ZVivoSim Labs (VIVS) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $VIVShttps://www.pharmaradar360.com/article/hypertension-clinical-trial-pipeline-accelerates-as-100-pharma-companies-rigorou-0af55f774e29cf90PharmaRadar360en2026-09-16T17:15:37.000ZHypertension Clinical Trial Pipeline Accelerates as 100+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsighthttps://www.pharmaradar360.com/article/examination-of-import-data-chemical-compounds-in-medicines-commonly-advertised-t-763641fbdc28ea5aPharmaRadar360en2026-09-16T17:14:20.000ZExamination Of Import Data: Chemical Compounds In Medicines Commonly Advertised To Consumershttps://www.pharmaradar360.com/article/where-will-novo-nordisk-be-in-5-years-as-the-glp-1-market-gets-more-crowded-b3961869c0ece775PharmaRadar360en2026-09-16T17:00:00.000ZWhere Will Novo Nordisk Be in 5 Years as the GLP-1 Market Gets More Crowded?https://www.pharmaradar360.com/article/south-korea-s-first-homegrown-obesity-drug-eppe-set-for-launch-this-year-challen-ab6bb3ea6dbff378PharmaRadar360en2026-09-16T16:58:31.000ZSouth Korea's First Homegrown Obesity Drug 'EPPE' Set for Launch This Year, Challenging Wegovy and Mounjaro at Half the Pricehttps://www.pharmaradar360.com/article/617-billion-longevity-biotech-market-takes-shape-72fd4fdc99cabefcPharmaRadar360en2026-09-16T16:56:10.000Z$617 billion longevity biotech market takes shapehttps://www.pharmaradar360.com/article/a-guide-to-sarms-definition-side-effects-and-dangers-e67630b4d57afdc1PharmaRadar360en2026-09-16T16:44:54.000ZA Guide to SARMs: Definition, Side Effects, and Dangershttps://www.pharmaradar360.com/article/pressure-cooker-pilot-destroys-pfas-in-sewage-but-scaling-up-is-a-challenge-e31e555c4cc81f97PharmaRadar360en2026-09-16T16:32:07.000Z‘Pressure cooker’ pilot destroys PFAS in sewage, but scaling up is a challengehttps://www.pharmaradar360.com/article/the-sucker-s-dilemma-the-psychology-of-getting-conned-e818af4adb86d4fdPharmaRadar360en2026-09-16T16:31:20.000ZThe sucker’s dilemma: The psychology of getting connedhttps://www.pharmaradar360.com/article/mamdani-s-consumer-cop-brings-lina-khan-s-playbook-to-nyc-5101674923b0f52ePharmaRadar360en2026-09-16T16:30:11.000ZMamdani’s Consumer Cop Brings Lina Khan’s Playbook to NYChttps://www.pharmaradar360.com/article/top-biotech-smidcap-stock-mizuho-analyst-highlights-immx-1a04bb2a75230e6ePharmaRadar360en2026-09-16T16:29:19.000ZTop BioTech SMidcap Stock: Mizuho Analyst Highlights IMMXhttps://www.pharmaradar360.com/article/ai-sustainability-modular-design-transform-pharmaceutical-manufacturing-094f4e78a7fc3cd5PharmaRadar360en2026-09-16T16:27:55.000ZAI, Sustainability, & Modular Design Transform Pharmaceutical Manufacturinghttps://www.pharmaradar360.com/article/how-do-you-know-if-the-beef-you-re-buying-is-from-the-usa-adcafe36f1d419d1PharmaRadar360en2026-09-16T16:27:43.000ZHow do you know if the beef you're buying is from the USA?https://www.pharmaradar360.com/article/farmers-face-significant-head-winds-this-fall-harvest-thanks-to-high-fuel-costs-a2e3ddf655702b09PharmaRadar360en2026-09-16T16:27:00.000ZFarmers face significant head winds this fall harvest thanks to high fuel costs and dryhttps://www.pharmaradar360.com/article/expanding-statewide-efforts-to-improve-heart-health-bbfbb0b44276a31fPharmaRadar360en2026-09-16T16:26:00.000ZExpanding statewide efforts to improve heart healthhttps://www.pharmaradar360.com/article/as-soybeans-near-harvest-rain-and-disease-questions-remain-16f415c0d0633923PharmaRadar360en2026-09-16T16:24:03.000ZAs soybeans near harvest, rain and disease questions remainhttps://www.pharmaradar360.com/article/where-will-novo-nordisk-be-in-5-years-as-the-glp-1-market-gets-more-crowded-4c2b98bd173a0af4PharmaRadar360en2026-09-16T16:20:00.000ZWhere Will Novo Nordisk Be in 5 Years as the GLP-1 Market Gets More Crowded?https://www.pharmaradar360.com/article/ingrid-zhang-a-new-leadership-chapter-at-legend-biotech-5d204a30db404f28PharmaRadar360en2026-09-16T16:14:51.000ZIngrid Zhang: A New Leadership Chapter at Legend Biotechhttps://www.pharmaradar360.com/article/ammonium-sulfate-fermentation-market-forecast-to-2035-biotech-demand-drives-grow-7089e7cb4d4ed2cfPharmaRadar360en2026-09-16T16:01:18.000ZAmmonium Sulfate Fermentation Market Forecast to 2035: Biotech Demand Drives Growth - News and Statisticshttps://www.pharmaradar360.com/article/ai-accelerates-biotech-promise-increasing-security-risks-86b42c82b5278c6dPharmaRadar360en2026-09-16T16:00:00.000ZAI accelerates biotech promise, increasing security riskshttps://www.pharmaradar360.com/article/heart-recipient-honours-organ-donors-with-transplant-games-overture-91018807af22fe2fPharmaRadar360en2026-09-16T15:50:48.000ZHeart recipient honours organ donors with Transplant Games overturehttps://www.pharmaradar360.com/article/gilead-reaches-hiv-prep-agreements-hong-kong-investigates-cloudbreak-ipo-9f9b09cdff1fc0b2PharmaRadar360en2026-09-16T15:37:00.000ZGilead reaches HIV PrEP agreements; Hong Kong investigates Cloudbreak IPOhttps://www.pharmaradar360.com/article/sicadi-resultados-de-categorizacion-de-docentes-investigadores-as-de-la-unlp-e34068010678089cPharmaRadar360en2026-09-16T15:36:44.000ZSICADI – Resultados de Categorización de Docentes Investigadores/as de la UNLPhttps://www.pharmaradar360.com/article/home-treatments-drive-smarter-sustainable-pharmaceutical-packaging-38172df7a6199e47PharmaRadar360en2026-09-16T15:34:53.000ZHome treatments drive smarter, sustainable pharmaceutical packaginghttps://www.pharmaradar360.com/article/raw-material-complexities-and-strategies-with-for-advanced-therapies-75982b30edb4c2d1PharmaRadar360en2026-09-16T15:33:47.000ZRaw Material Complexities and Strategies with for Advanced Therapieshttps://www.pharmaradar360.com/article/legionellosis-in-residents-of-england-and-wales-2025-ddbdab6f2a833e23PharmaRadar360en2026-09-16T15:33:27.000ZLegionellosis in residents of England and Wales: 2025https://www.pharmaradar360.com/article/nasa-hubble-fellowship-program-2027-803e4575d6d906d0PharmaRadar360en2026-09-16T15:25:40.000ZNASA Hubble Fellowship Program 2027https://www.pharmaradar360.com/article/from-counting-sheep-to-forty-winks-three-tips-to-get-your-kids-back-on-a-healthy-a507f783ecee492dPharmaRadar360en2026-09-16T15:25:00.000ZFrom counting sheep to forty winks: three tips to get your kids back on a healthy sleep schedulehttps://www.pharmaradar360.com/article/cooking-class-livestream-italian-ground-turkey-frittata-d84cf9acb61ad274PharmaRadar360en2026-09-16T15:09:15.000ZCooking Class Livestream: Italian Ground Turkey Frittatahttps://www.pharmaradar360.com/article/european-adrs-inched-up-as-telecom-and-biotech-led-472ac474aa915400PharmaRadar360en2026-09-16T15:08:41.000ZEuropean ADRs Inched Up As Telecom And Biotech Ledhttps://www.pharmaradar360.com/article/montana-s-giving-the-biotech-industry-sweeping-authority-to-sell-unapproved-drug-2190e459be361d76PharmaRadar360en2026-09-16T15:07:00.000ZMontana’s giving the biotech industry sweeping authority to sell unapproved drugshttps://www.pharmaradar360.com/article/naoko-takebe-md-phd-joins-wilmot-to-build-early-phase-clinical-trials-and-develo-7441cb8dd9acd00ePharmaRadar360en2026-09-16T15:04:05.000ZNaoko Takebe, MD, PhD, Joins Wilmot to Build Early-Phase Clinical Trials and Developmental Therapeuticshttps://www.pharmaradar360.com/article/cold-mortality-monitoring-report-england-winter-2024-to-2025-6966878552215588PharmaRadar360en2026-09-16T15:00:05.000ZCold mortality monitoring report, England: winter 2024 to 2025https://www.pharmaradar360.com/article/kibow-biotech-wins-2026-webaward-for-best-science-website-52d6a8ecf05d157cPharmaRadar360en2026-09-16T15:00:00.000ZKibow® Biotech Wins 2026 WebAward for Best Science Websitehttps://www.pharmaradar360.com/article/glp-1s-what-is-behind-the-variation-in-efficacy-f2db9c17e19f1a25PharmaRadar360en2026-09-16T14:58:01.000ZGLP-1s: what is behind the variation in efficacy?https://www.pharmaradar360.com/article/bauchaortenaneurysma-nach-evar-neue-wege-zur-besseren-nachsorge-fad268c1acffb4b9PharmaRadar360en2026-09-16T14:57:05.000ZBauchaortenaneurysma nach EVAR – neue Wege zur besseren Nachsorgehttps://www.pharmaradar360.com/article/compras-y-contrataciones-ab71a6a5fe0835ecPharmaRadar360en2026-09-16T14:53:26.000ZCompras y Contratacioneshttps://www.pharmaradar360.com/article/drug-shortages-a426e4f99d62d81aPharmaRadar360en2026-09-16T14:50:19.000ZDrug Shortageshttps://www.pharmaradar360.com/article/law-firm-leader-to-chair-2026-long-island-heart-stroke-ball-ff797735c0b6f755PharmaRadar360en2026-09-16T14:47:00.000ZLaw firm leader to chair 2026 Long Island Heart & Stroke Ballhttps://www.pharmaradar360.com/article/vivre-avec-et-apres-un-cancer-les-promesses-et-les-defis-de-la-sante-numerique-945e8a65c5d7a4f3PharmaRadar360en2026-09-16T14:46:47.000ZVivre avec et après un cancer : les promesses et les défis de la santé numériquehttps://www.pharmaradar360.com/article/estates-safety-fund-initial-schemes-and-associated-funding-allocations-2026-to-2-578511fd55580096PharmaRadar360en2026-09-16T14:42:12.000ZEstates Safety Fund: initial schemes and associated funding allocations, 2026 to 2030https://www.pharmaradar360.com/article/novartis-ends-als-program-after-phase-2-flop-adding-to-r-d-woes-da0b1c01b0e1cfd3PharmaRadar360en2026-09-16T14:28:27.000ZNovartis ends ALS program after phase 2 flop, adding to R&D woeshttps://www.pharmaradar360.com/article/buy-european-incentivising-eu-based-pharmaceutical-manufacturing-f0be7ec5d4a13c8dPharmaRadar360en2026-09-16T14:23:57.000ZBuy European: Incentivising EU Based Pharmaceutical Manufacturinghttps://www.pharmaradar360.com/article/people-on-the-move-ingrid-zhang-named-chief-executive-officer-of-legend-biotech-fa8e3ddf53ecd71aPharmaRadar360en2026-09-16T14:17:01.000ZPeople on the Move: Ingrid Zhang Named Chief Executive Officer of Legend Biotechhttps://www.pharmaradar360.com/article/sling-therapeutics-announces-first-patients-dosed-in-global-phase-3-orbit-pivota-493b66e4547da753PharmaRadar360en2026-09-16T14:12:34.000ZSling Therapeutics Announces First Patients Dosed in Global Phase 3 ORBIT Pivotal Trial of Linsitinib for Thyroid Eye Diseasehttps://www.pharmaradar360.com/article/legend-biotech-names-novartis-veteran-ingrid-zhang-as-new-ceo-c36c83304cfb057bPharmaRadar360en2026-09-16T14:12:29.000ZLegend Biotech names Novartis veteran Ingrid Zhang as new CEOhttps://www.pharmaradar360.com/article/rassegnastampa-disagio-adolescenziale-in-lombardia-25mila-accessi-in-ps-policlin-daa6272d4426e2dcPharmaRadar360en2026-09-16T14:12:00.000Z#RASSEGNASTAMPA. Disagio adolescenziale, in Lombardia 25mila accessi in ps: Policlinico Kids 2.0 a Sky TG24https://www.pharmaradar360.com/article/acrp-unveils-theme-for-2027-annual-conference-d04f966c0b3615d9PharmaRadar360en2026-09-16T14:09:13.000ZACRP Unveils Theme for 2027 Annual Conferencehttps://www.pharmaradar360.com/article/scientists-find-an-immune-false-alarm-that-may-drive-rapid-aging-00104e3c1b86bb4ePharmaRadar360en2026-09-16T14:05:35.000ZScientists find an immune “false alarm” that may drive rapid aginghttps://www.pharmaradar360.com/article/an-engineered-bacterial-symbiont-maps-micron-scale-sugar-gradients-in-the-honeyb-c00843ed0d57862aPharmaRadar360en2026-09-16T14:00:00.000ZAn engineered bacterial symbiont maps micron-scale sugar gradients in the honeybee guthttps://www.pharmaradar360.com/article/turning-a-phage-anti-defense-weapon-into-an-immunity-trigger-93d45ca39f2aeaaePharmaRadar360en2026-09-16T14:00:00.000ZTurning a phage anti-defense weapon into an immunity triggerhttps://www.pharmaradar360.com/article/spamoal-is-a-deep-learning-method-that-enables-accurate-spatial-domain-identific-cf38688d6c4c0b39PharmaRadar360en2026-09-16T14:00:00.000ZSpaMOAL is a deep learning method that enables accurate spatial domain identification from multi-omics datahttps://www.pharmaradar360.com/article/celebrating-what-holds-us-on-iphone-18-pro-f697be91e8bd515cPharmaRadar360en2026-09-16T13:59:28.000ZCelebrating “What Holds Us” on iPhone 18 Prohttps://www.pharmaradar360.com/article/supreme-court-preserves-broad-access-to-abortion-drug-mifepristone-7f64cc35a1f5e3e3PharmaRadar360en2026-09-16T13:58:17.000ZSupreme Court preserves broad access to abortion drug mifepristonehttps://www.pharmaradar360.com/article/carolina-housing-is-built-on-student-feedback-2c16247fc949a7a2PharmaRadar360en2026-09-16T13:58:05.000ZCarolina Housing is built on student feedbackhttps://www.pharmaradar360.com/article/eschback-launches-leader-standard-work-capability-in-seqonis-platform-d6bbb1809a7eb5ffPharmaRadar360en2026-09-16T13:54:48.000Zeschback launches Leader Standard Work capability in Seqonis platformhttps://www.pharmaradar360.com/article/collegium-pharmaceutical-at-h-c-wainwright-pushing-beyond-pain-by-investing-com-7acb87745e02bc6aPharmaRadar360en2026-09-16T13:45:04.000ZCollegium Pharmaceutical at H.C. Wainwright: pushing beyond pain By Investing.comhttps://www.pharmaradar360.com/article/arrowhead-achieves-clinical-validation-for-new-drug-platform-a8d024929ce7f48ePharmaRadar360en2026-09-16T13:39:14.000ZArrowhead Achieves Clinical Validation for New Drug Platformhttps://www.pharmaradar360.com/article/sen-warren-demands-to-see-trump-drug-pricing-pharma-contracts-accuses-rfk-jr-of-b2c1b39832ead5dbPharmaRadar360en2026-09-16T13:36:24.000ZSen. Warren demands to see Trump drug-pricing pharma contracts, accuses RFK Jr. of hiding themhttps://www.pharmaradar360.com/article/optimi-health-launches-phase-3-mdma-assisted-therapy-trial-for-ptsd-targeting-ve-9bb879d09f021f92PharmaRadar360en2026-09-16T13:35:54.000ZOptimi Health Launches Phase 3 MDMA-Assisted Therapy Trial for PTSD Targeting Veterans and Frontline Workershttps://www.pharmaradar360.com/article/what-can-our-genes-tell-us-about-preventing-myeloma-fb0d068098d74476PharmaRadar360en2026-09-16T13:31:31.000ZWhat can our genes tell us about preventing myeloma?https://www.pharmaradar360.com/article/10-ai-biotech-firms-in-northern-metropolis-to-get-early-cross-border-data-access-8d6ce46540846e4ePharmaRadar360en2026-09-16T13:31:25.000Z10 AI, biotech firms in Northern Metropolis to get early cross-border data accesshttps://www.pharmaradar360.com/article/heart-risks-provider-misconduct-and-a-21-year-old-s-death-sharpen-safety-warning-5194dfbd227784a9PharmaRadar360en2026-09-16T13:30:10.000ZHeart Risks, Provider Misconduct, and a 21-Year-Old's Death Sharpen Safety Warnings as FDA Weighs Psychedelic Carehttps://www.pharmaradar360.com/article/heart-risks-provider-misconduct-and-a-21-year-old-s-6b7a9c26ed278664PharmaRadar360en2026-09-16T13:30:10.000ZHeart Risks, Provider Misconduct, and a 21-Year-Old's…https://www.pharmaradar360.com/article/covid-19-vaccination-information-for-healthcare-practitioners-2a8cecfc3a4c1e42PharmaRadar360en2026-09-16T13:30:00.000ZCOVID-19 vaccination: information for healthcare practitionershttps://www.pharmaradar360.com/article/the-pbm-entity-no-pharmaceutical-company-directly-contracted-with-15e0f87edc35ede0PharmaRadar360en2026-09-16T13:18:37.000ZThe PBM Entity No Pharmaceutical Company Directly Contracted Withhttps://www.pharmaradar360.com/article/pre-submission-advice-support-for-innovative-medicines-b8e46373a16aa9afPharmaRadar360en2026-09-16T13:16:15.000ZPre-submission Advice & Support for Innovative Medicineshttps://www.pharmaradar360.com/article/national-assessment-procedure-for-medicines-5034d11e20bd2b10PharmaRadar360en2026-09-16T13:15:35.000ZNational assessment procedure for medicineshttps://www.pharmaradar360.com/article/biotech-pre-market-movers-meds-tpst-cupr-chart-the-course-b8cbe9650f92187bPharmaRadar360en2026-09-16T13:15:00.000ZBiotech Pre-Market Movers: MEDS, TPST, CUPR Chart The Coursehttps://www.pharmaradar360.com/article/medicines-apply-for-a-variation-to-your-marketing-authorisation-bc0e2a85d91fcf38PharmaRadar360en2026-09-16T13:14:52.000ZMedicines: apply for a variation to your marketing authorisationhttps://www.pharmaradar360.com/article/un-projet-de-recherche-pour-en-finir-avec-le-risque-de-noyade-des-personnes-lary-6ad6ce0ec9a9cf84PharmaRadar360en2026-09-16T13:13:47.000ZUn projet de recherche pour en finir avec le risque de noyade des personnes laryngectomiséeshttps://www.pharmaradar360.com/article/legend-biotech-names-ex-novartis-exec-as-ceo-601341f40ad47d08PharmaRadar360en2026-09-16T13:10:17.000ZLegend Biotech names ex-Novartis exec as CEOhttps://www.pharmaradar360.com/article/calgary-based-biotech-founders-announced-as-recipients-of-canada-s-top-40-under-01c6c7755adde338PharmaRadar360en2026-09-16T13:10:00.000ZCalgary-Based Biotech Founders Announced as Recipients of Canada's Top 40 Under 40® Award for 2026https://www.pharmaradar360.com/article/sinphar-pharmaceutical-fy2026-h1-earnings-call-gross-margin-hits-record-45-4-aug-2c92cc8d92f59c34PharmaRadar360en2026-09-16T13:04:00.000Z[Sinphar Pharmaceutical FY2026 H1 Earnings Call] Gross Margin Hits Record 45.4%, August Revenue Surges 21.6% YoY; NT$700 Million Yilan Smart Logistics Center Aims to Capture Japan and ASEAN Ordershttps://www.pharmaradar360.com/article/ori-locks-down-120m-pact-to-deploy-automated-production-platform-for-unnamed-com-dedd8983f9a5d6b6PharmaRadar360en2026-09-16T13:02:30.000ZOri locks down $120M pact to deploy automated production platform for unnamed commercial cell therapyhttps://www.pharmaradar360.com/article/notifiable-diseases-causative-agents-reports-for-2026-32900b46450305d4PharmaRadar360en2026-09-16T13:00:01.000ZNotifiable diseases: causative agents reports for 2026https://www.pharmaradar360.com/article/covid-19-vaccine-5-years-and-over-pgd-and-vgd-6776102a716b3a92PharmaRadar360en2026-09-16T13:00:01.000ZCOVID-19 vaccine (5 years and over) PGD and VGDhttps://www.pharmaradar360.com/article/covid-19-the-green-book-chapter-d276b249e49e4dc1PharmaRadar360en2026-09-16T13:00:01.000ZCOVID-19: the green book chapterhttps://www.pharmaradar360.com/article/finally-a-chance-to-breathe-christiana-gets-care-for-hirschsprung-s-disease-c3e13beb67f44b5aPharmaRadar360en2026-09-16T13:00:00.000ZFinally a chance to breathe: Christiana gets care for Hirschsprung’s diseasehttps://www.pharmaradar360.com/article/pharmaceutical-manufacturing-plant-setup-in-india-9388a1cfa87e6157PharmaRadar360en2026-09-16T12:54:07.000ZPharmaceutical Manufacturing Plant Setup in Indiahttps://www.pharmaradar360.com/article/scientists-find-the-whole-grain-sweet-spot-for-better-heart-health-74fe8c2892b5b3afPharmaRadar360en2026-09-16T12:52:48.000ZScientists find the whole grain “sweet spot” for better heart healthhttps://www.pharmaradar360.com/article/ufrj-concede-titulo-de-professora-emerita-a-ana-luiza-coelho-netto-07641e2218bdf689PharmaRadar360en2026-09-16T12:52:12.000ZUFRJ concede título de Professora Emérita à Ana Luiza Coelho Nettohttps://www.pharmaradar360.com/article/oncology-biotech-news-key-moves-to-watch-in-september-2026-78cb8609a164864fPharmaRadar360en2026-09-16T12:42:22.000ZOncology biotech news: key moves to watch in September 2026https://www.pharmaradar360.com/article/west-pharmaceutical-cuts-98-scottsdale-jobs-after-product-sale-02c12ed5bda7592ePharmaRadar360en2026-09-16T12:39:00.000ZWest Pharmaceutical cuts 98 Scottsdale jobs after product salehttps://www.pharmaradar360.com/article/novartis-pays-sironax-125m-to-acquire-platform-for-crossing-the-blood-brain-barr-57efc9bfdd6fbe18PharmaRadar360en2026-09-16T12:32:15.000ZNovartis pays Sironax $125M to acquire platform for crossing the blood-brain barrierhttps://www.pharmaradar360.com/article/ciclo-de-talleres-para-investigadores-de-la-unlp-2026-tercera-edicion-d1bb67ca66d66070PharmaRadar360en2026-09-16T12:31:46.000ZCiclo de talleres para investigadores de la UNLP 2026 | Tercera ediciónhttps://www.pharmaradar360.com/article/vivosim-labs-unveils-new-namkindtm-drug-toxicity-data-at-eurotox-2026-demonstrat-7c307c64eb413c4ePharmaRadar360en2026-09-16T12:26:15.000ZVivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs